Novo Nordisk - Class B Shares NOVO B
Dividend Summary
The next Novo Nordisk - Class B Shares dividend is expected to go ex in 4 months and to be paid in 4 months.
The previous Novo Nordisk - Class B Shares dividend was 350öre and it went ex 4 months ago and it was paid 4 months ago.
There are typically 2 dividends per year (excluding specials), and the dividend cover is approximately 2.5.
Latest Dividends
| Summary | Previous dividend | Next dividend |
|---|---|---|
| Status | Paid | Forecast |
| Type | Interim | Final |
| Per share | 350öre | Sign Up Required |
| Declaration date | 07 Aug 2024 (Wed) | 29 Jan 2025 (Wed) |
| Ex-div date | 15 Aug 2024 (Thu) | 28 Mar 2025 (Fri) |
| Pay date | 19 Aug 2024 (Mon) | 01 Apr 2025 (Tue) |
Enter the number of Novo Nordisk - Class B Shares shares you hold and we'll calculate your dividend payments:
Previous Payment
kr.350
Paid on 19 Aug 2024 (Mon)
Free Email Notification
Sign up for Novo Nordisk - Class B Shares and we'll email you the dividend information when they declare.
Add Novo Nordisk - Class B Shares to receive free notifications when they declare their dividends.
Your account is set up to receive Novo Nordisk - Class B Shares notifications.
The table below shows the full dividend history for Novo Nordisk - Class B Shares
| Status | Type | Decl. date | Ex-div date | Pay date | Decl. Currency | Forecast amount | Decl. amount | Accuracy |
|---|---|---|---|---|---|---|---|---|
| Forecast | Final | 24 Jan 2029 | 23 Mar 2029 | 27 Mar 2029 | DKK | Sign up | — | |
| Forecast | Interim | 02 Aug 2028 | 10 Aug 2028 | 14 Aug 2028 | DKK | Sign up | — | |
| Forecast | Final | 26 Jan 2028 | 24 Mar 2028 | 28 Mar 2028 | DKK | Sign up | — | |
| Forecast | Interim | 04 Aug 2027 | 12 Aug 2027 | 16 Aug 2027 | DKK | Sign up | — | |
| Forecast | Final | 27 Jan 2027 | 26 Mar 2027 | 30 Mar 2027 | DKK | Sign up | — | |
| Forecast | Interim | 05 Aug 2026 | 13 Aug 2026 | 17 Aug 2026 | DKK | Sign up | — | |
| Forecast | Final | 28 Jan 2026 | 27 Mar 2026 | 31 Mar 2026 | DKK | Sign up | — | |
| Forecast | Interim | 06 Aug 2025 | 14 Aug 2025 | 18 Aug 2025 | DKK | Sign up | — | |
| Forecast | Final | 29 Jan 2025 | 28 Mar 2025 | 01 Apr 2025 | DKK | Sign up | — | |
| Paid | Interim | 07 Aug 2024 | 15 Aug 2024 | 19 Aug 2024 | DKK | 390öre | 350öre | 😏 |
| Paid | Final | 31 Jan 2024 | 22 Mar 2024 | 26 Mar 2024 | DKK | 640öre | 640öre | 😄 |
| Paid | Interim | 10 Aug 2023 | 18 Aug 2023 | 22 Aug 2023 | DKK | 496öre | 600öre | 😌 |
| Paid | Final | 22 Mar 2023 | 24 Mar 2023 | 28 Mar 2023 | DKK | 838öre | 815öre | 😃 |
| Paid | Interim | 11 Aug 2022 | 15 Aug 2022 | 16 Aug 2022 | DKK | 391öre | 425öre | 😊 |
| Paid | Final | 02 Feb 2022 | 25 Mar 2022 | 29 Mar 2022 | DKK | 630öre | 690öre | 😊 |
| Paid | Interim | – | 16 Aug 2021 | 18 Aug 2021 | DKK | 344öre | 350öre | 😃 |
| Paid | Final | – | 26 Mar 2021 | 30 Mar 2021 | DKK | 550öre | 585öre | 😊 |
| Paid | Interim | 18 Aug 2020 | 14 Aug 2020 | 18 Aug 2020 | DKK | 278öre | 325öre | 😌 |
| Paid | Final | – | 27 Mar 2020 | 31 Mar 2020 | DKK | 515öre | 535öre | 😃 |
| Paid | Interim | – | 16 Aug 2019 | 20 Aug 2019 | DKK | 311öre | 300öre | 😃 |
| Paid | Final | – | 22 Mar 2019 | 26 Mar 2019 | DKK | — | 515öre | |
| Paid | Interim | 07 Aug 2018 | 17 Aug 2018 | 28 Aug 2018 | DKK | 320öre | 300öre | 😊 |
| Paid | Final | – | 23 Mar 2018 | 27 Mar 2018 | DKK | — | 485öre | |
| Paid | Interim | 10 Aug 2017 | 18 Aug 2017 | 22 Aug 2017 | DKK | 350öre | 300öre | 😌 |
| Paid | Final | – | 24 Mar 2017 | 28 Mar 2017 | DKK | 680öre | 460öre | 😞 |
| Paid | Interim | 05 Aug 2016 | 12 Aug 2016 | 16 Aug 2016 | DKK | — | 300öre | |
| Paid | Final | 03 Feb 2016 | 21 Mar 2016 | 23 Mar 2016 | DKK | — | 640öre | |
| Paid | Final | – | 20 Mar 2015 | 25 Mar 2015 | DKK | — | 500öre | |
| Paid | Final | – | 21 Mar 2014 | 26 Mar 2014 | DKK | — | 450öre | |
| Paid | Final | – | 21 Mar 2013 | 26 Mar 2013 | DKK | — | 360öre | |
| Paid | Final | – | 24 Mar 2011 | 29 Mar 2011 | DKK | — | 200öre | |
| Paid | Final | – | 25 Mar 2010 | 30 Mar 2010 | DKK | — | 150öre | |
| Paid | Final | – | 19 Mar 2009 | 23 Mar 2009 | DKK | — | 120öre | |
| Paid | Final | – | 13 Mar 2008 | 18 Mar 2008 | DKK | — | 90öre | |
| Paid | Final | – | 08 Mar 2007 | 13 Mar 2007 | DKK | — | 70öre | |
| Paid | Final | – | 09 Mar 2006 | 14 Mar 2006 | DKK | — | 60öre |
| Year | Amount | Change |
|---|---|---|
| 2006 | 70.0öre | — |
| 2007 | 90.0öre | 28.6% |
| 2008 | 0.0öre | -100.0% |
| 2009 | 270.0öre | 100% |
| 2010 | 0.0öre | -100.0% |
| 2011 | 200.0öre | 100% |
| 2012 | 360.0öre | 80.0% |
| 2013 | 450.0öre | 25.0% |
| 2014 | 500.0öre | 11.1% |
| 2015 | 640.0öre | 28.0% |
| 2016 | 760.0öre | 18.8% |
| 2017 | 785.0öre | 3.3% |
| 2018 | 815.0öre | 3.8% |
| 2019 | 835.0öre | 2.5% |
| 2020 | 910.0öre | 9.0% |
| 2021 | 1040.0öre | 14.3% |
| 2022 | 1240.0öre | 19.2% |
| 2023 | 1240.0öre | 0% |
| 2024 | Sign Up Required | |
| 2025 | Sign Up Required | |
| 2026 | Sign Up Required | |
| 2027 | Sign Up Required | |
| 2028 | Sign Up Required | |
Novo Nordisk Optimized Dividend Chart
The chart below shows the optimized dividends for this security over a rolling 12-month period.
- Dividend Yield Today
- 1.4%
- Optimized Yield
- Sign Up Required
- 52 Week High
- 2.1% on 29 February 2024
- 52 Week Low
- 1.3% on 15 August 2024
- Next Ex-Div-Date Countdown
- Sign Up Required
About Novo Nordisk
Novo Nordisk is a pharmaceutical company focussed on diabetes treatment. It also operates in haemostasis management, growth hormone therapy and hormone replacement therapy. It employs over 26,000 people across 79 countries and markets its products in 180 countries.
- Sector
- Pharmaceuticals & Biotechnology
- Country
- Denmark
- Share Price
- kr.775.80 (yesterday's closing price)
- Shares in Issue
- 3,390 million
- Market Cap
- kr.2630.1bn
- 2.5
- 0
- Market Indices
- OMX Copenhagen 20, STOXX600
- Other listings
- Novo Nordisk, Novo Nordisk - ADR
- Investor Relations URL
- Sign Up Required
- Home Page URL
- https://www.novonordisk.com/
- Dividend History URL
- Sign Up Required
- Financial Calendar URL
- Sign Up Required
Effectiveness and Issues of Celebrity Endorsement in Global Pharmaceutical Industry: Novo Nordisk Case
Celebrity endorsement in the global pharmaceutical industry has always been a controversial subject. On the one hand, celebrity promotion enables millions of people to get awareness of the medication suitable for their existing health needs. On the other hand, celebrity promotion presents a set of regulatory and ethical problems that can cause detrimental harm by replacing professional medical advice with unscientific personal testimonials.
